Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis
Background and Objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
SL Hauser, A Bar-Or, MS Weber, H Kletzl… - 2023 - publications.goettingen-research …
Background and Objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
Association of Higher Ocrelizumab Exposure with Reduced Disability Progression in Multiple Sclerosis
S Hauser, A Bar-Or, M Weber, H Kletzl, A Günther… - 2023 - publica.fraunhofer.de
BACKGROUND AND OBJECTIVES: Ocrelizumab improved clinical and MRI measures of
disease activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc …
disease activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc …
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
SL Hauser, A Bar-Or, MS Weber, H Kletzl… - Neurology (R) …, 2023 - escholarship.org
Background and objectivesOcrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
[HTML][HTML] Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
SL Hauser, A Bar-Or, MS Weber, H Kletzl… - Neurology® …, 2023 - ncbi.nlm.nih.gov
Methods Patients in OPERA I/II and ORATORIO were grouped in exposure quartiles based
on their observed individual serum ocrelizumab level over the treatment period. Exposure …
on their observed individual serum ocrelizumab level over the treatment period. Exposure …
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
SL Hauser, A Bar-Or, MS Weber, H Kletzl, A Günther… - 2023 - pubmed.ncbi.nlm.nih.gov
Background and objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
[HTML][HTML] Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
SL Hauser, A Bar-Or, MS Weber, H Kletzl… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
SL Hauser, A Bar-Or, MS Weber, H Kletzl… - Neurology (r) …, 2023 - europepmc.org
Methods Patients in OPERA I/II and ORATORIO were grouped in exposure quartiles based
on their observed individual serum ocrelizumab level over the treatment period. Exposure …
on their observed individual serum ocrelizumab level over the treatment period. Exposure …
[引用][C] Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
Neurology-Neuroimmunology Neuroinflammation, 2023 - AAN Enterprises
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
Neurology® Neuroimmunology & Neuroinflammation, 2023 - europepmc.org
Methods Patients in OPERA I/II and ORATORIO were grouped in exposure quartiles based
on their observed individual serum ocrelizumab level over the treatment period. Exposure …
on their observed individual serum ocrelizumab level over the treatment period. Exposure …